                         SEQUENCE LISTING

<110>  MEDIMMUNE, LLC
 
<120>  TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND 
       CHEMOTHERAPY

<130>  CD73-211-WO-PCT

<150>  US 63/084,900
<151>  2020-09-29

<150>  US 63/082,162
<151>  2020-09-23

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VL

<400>  1

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Leu Ser Asn Ile Gly Arg Asn 
            20                  25                  30          


Pro Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Leu Asp Asn Leu Arg Leu Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser His 
                85                  90                  95      


Pro Gly Trp Thr Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  2
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VH

<400>  2

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Tyr Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Tyr Gly Arg Val Asp Glu Trp Gly Arg Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VH CDR1

<400>  3

Ser Tyr Ala Tyr Ser 
1               5   


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VH CDR2

<400>  4

Ala Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  5
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VH CDR3

<400>  5

Leu Gly Tyr Gly Arg Val Asp Glu 
1               5               


<210>  6
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VL CDR1

<400>  6

Ser Gly Ser Leu Ser Asn Ile Gly Arg Asn Pro Val Asn 
1               5                   10              


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VL CDR2

<400>  7

Leu Asp Asn Leu Arg Leu Ser 
1               5           


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oleclumab VL CDR3

<400>  8

Ala Thr Trp Asp Asp Ser His Pro Gly Trp Thr 
1               5                   10      


<210>  9
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VL

<400>  9

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  10
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VH

<400>  10

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  11
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VH CDR1

<400>  11

Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser 
1               5                   10  


<210>  12
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VH CDR2

<400>  12

Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  13
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VH CDR3

<400>  13

Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr 
1               5                   10          


<210>  14
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VL CDR1

<400>  14

Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu Ala 
1               5                   10          


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VL CDR2

<400>  15

Asp Ala Ser Ser Arg Ala Thr 
1               5           


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab VL CDR3

<400>  16

Gln Gln Tyr Gly Ser Leu Pro Trp Thr 
1               5                   


